Share This
Create Your Own Business Intelligence Website
 
Input the stock code or the company name     Search  

<00460.HK> - Sihuan Pharmaceutical Holdings Group Ltd.

 
 
 Basic Datum
Company name Lot P/E P/B EPS DPS
SIHUAN PHARM 1000 -102.23 1.0178 -0.0064 0.0
Profile Information Data Financial Ratios Profit Loss Cash Flow Balance Earnings Dividend
 
 
 
 Company Rating
Date Broker Company name Rating Target
≫More
 
 Company performance - Published
Date Company name Turnover* Profit* % Dividend
≫More
 
 Comment
2024-11-26　的司美格魯肽化合物專利到期前，四環醫藥研發的生物仿制藥不能上市銷售。考慮到其他競爭對手的研發進度及產品迭代速度，四環醫藥的減肥藥上市後將面臨劇烈競爭。
 
2024-11-26　四環醫藥公布公告稱，其旗下非全資附屬公司惠升生物與另一非全資附屬公司渼顏空間達成獨家授權合作，涉及惠升生物研發的用於減重的司美格魯肽注射液。該注射液作為一種長效ＧＬＰ-１受體激動劑，已在中國大陸地區得到減重適應症的臨床批准，並且在２型糖尿病適應症方面已完成ＩＩＩ期臨床入組。
 
2024-12-03　１１月２５日，港交所官網顯示，軒竹生物科技股權有限公司（簡稱「軒竹生物」）遞交上市申請。這一轉戰港股的消息並不突然。１１月１２日，四環醫藥就曾公告，建議分拆軒竹生物的股權並於聯交所主板上市，且公司已獲得聯交所關於其依據上市規則第１５項應用指引建議分拆軒竹生物的批准。同一時間，四環醫藥以總價約３．０８億元進一步收購軒竹生物約３．６１７７％的股權。
 
 
 Top Gain / Loss Show All Charts 
 
 Value
Name Updated Value Change Change %
HSI 01-13 09:30 18846.2 ▼ 218.14 ▼ 1.14%
SIHUAN PHARM 05-08 13:03 0.6 ▲ 0.6 ▲ ∞%
≫More
 
 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.